Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of CAD 7.65 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2015-03-13
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was 7.65M CAD, a 1288.38% increase from fiscal 2013.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2013 was 551.00K CAD, a 571.95% increase from fiscal 2012.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2012 was 82.00K CAD.
CAD
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2014-12-31 | 7.65M CAD 10-K · filed 2015-03-13 |
| 2013-12-31 | 551.00K CAD 10-K · filed 2015-03-13 |
| 2012-12-31 | 82.00K CAD 10-K · filed 2015-03-13 |
| 2011-12-31 | 42.62K CAD 20-F · filed 2013-03-27 |
USD
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2014-12-31 | $6.93M 10-K · filed 2015-03-13 | |
| 2013-12-31 | $535.00K 10-K · filed 2015-03-13 | |
| 2012-12-31 | $82.00K 10-K · filed 2015-03-13 | $18.94K 6-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |